scholarly journals Big Data Information under Proportional Hazard Mathematical Model in Analysis of Hepatitis B Virus Infection Data of Patients with Interventional Liver Cancer through Antiviral Therapy of Entecavir

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Yichi Zhang ◽  
Shuai Zhao ◽  
Han Ding ◽  
Xiaoling Song ◽  
Huijie Miao ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Hepatitis B ◽  
Antiviral Therapy ◽  
Conversion Rate ◽  
Primary Liver Cancer ◽  
Hbv Dna ◽  
Control Group ◽  
Proportional Hazard ◽  
B Virus ◽  
Experimental Group

The objective of this study was to analyze the application of proportional hazard mathematical model (PHMM) in Hepatitis B Virus (HBV) infection analysis of interventional liver cancer patients treated with entecavir, so as to provide data support for clinical diagnosis and treatment. Based on the survival analysis, the treatment factor x was undertaken as an independent variable to perform linear regression. The regression model took the hazard rate function as the dependent variable to establish an exponential regression equation to construct a PHMM. 136 patients with primary liver cancer receiving interventional chemoembolization combined with the drug (entecavir) were selected as the experimental group, who were in the computer gene expression omnibus (GEO). 87 patients with primary liver cancer who underwent interventional chemoembolization therapy without antiviral treatment were taken as the control group. The PHMM was adopted for comprehensive analysis. In addition, the factors affecting the virological response to antiviral therapy were analyzed using the multiple logistic regression. The results revealed that HBV deoxyribonucleic acid (DNA) negative conversion rate, Hepatitis B e-Antigen (HBeAg) negative conversion rate, and HBeAg serological conversion rate in the experimental group were much higher than those in the control group ( P < 0.05 ). HBV DNA level and proportion of HBsAg <100 IU/mL in the experimental group were much lower than those in the control group ( P < 0.05 ). The virological breakthrough rate and incidence of adverse events at week 24 in the experimental group were greatly lower than those in the control group ( P < 0.05 ). The adverse virological response of patient was positively correlated with HBV DNA load and HBeAg status and negatively correlated with alanine aminotransferase (ALT) level ( P < 0.05 ). Therefore, entecavir can significantly inhibit HBV DNA replication in patients with liver cancer, showing high antiviral effect. High baseline HBV DNA load, positive HBeAg, and low baseline alanine aminotransferase levels were independent risk factors for adverse virology response to entecavir antiviral therapy, which provided a reference for the selection of antiviral drugs for HBV infection.

Hepatitis B vaccine

1985 ◽  
Vol 23 (13) ◽  
pp. 49-51
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B Virus ◽  
Liver Cancer ◽  
Hepatitis B ◽  
Acute Hepatitis ◽  
World Wide ◽  
Primary Liver Cancer ◽  
Hepatitis B Vaccine ◽  
Common Cause ◽  
B Virus

The hepatitis B virus is the most common cause world-wide of acute hepatitis, and also causes chronic hepatitis, cirrhosis1 and primary liver cancer.2 It can now be prevented by a vaccine. How should this best be used?

scholarly journals Clinical characteristics of patients with hepatitis B virus related liver cirrhosis and primary liver cancer

2015 ◽  
Vol 23 (17) ◽  
pp. 2798
Author(s):  
Feng Lv ◽  
Yu-Feng Gao ◽  
Jian-Guo Rao ◽  
Wei Zhang ◽  
Gui-Zhou Zou ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Hepatitis B Virus ◽  
Liver Cancer ◽  
Hepatitis B ◽  
Clinical Characteristics ◽  
Primary Liver Cancer ◽  
B Virus

The possible role of S gene mutations of hepatitis B virus in intrauterine transmission

2020 ◽  
Author(s):  
Jiaxin Wu ◽  
Yongliang Feng ◽  
Zhiqing Yang ◽  
Ruijun Zhang ◽  
Dandan Wang ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hepatitis B Surface Antigen ◽  
Gene Mutations ◽  
Hbv Dna ◽  
Mutation Rates ◽  
Control Group ◽  
Intrauterine Transmission ◽  
S Gene ◽  
B Virus

Abstract Background: Many hepatitis B virus (HBV) substances could inevitably enter fetuses and occurred neonatal intrauterine transmission. HBV often occurs mutation, especially S gene, and may lead to different outcomes on intrauterine transmission. We explored the associations between HBV S gene mutations of hepatitis B surface antigen positive (HBsAg-positive) mothers and intrauterine transmission. Methods: A total of 399 HBsAg-positive mothers and neonates were recruited and their general demographic information was collected between June 2011 and July 2013. The mothers with HBV DNA levels ≥ 106 IU/ml were selected, 22 mothers whose neonates occurred HBV intrauterine transmission were in the HBV intrauterine transmission group (GT) and 22 mothers were randomly selected from the remaining controls were in the control group (GC). Maternal whole-genome HBV DNA was extracted, amplified, cloned, and sequenced. Obtained sequences were adjusted, genotyped, and analyzed for mutation rates. A case-control study was designed to analyze the relationship between mutations in the S gene of HBV and intrauterine transmission. Results: Fifty-five neonates were found to have experienced intrauterine transmission (13.78%). Genotype B (4.55%), genotype C (88.64%) and inter-genotype B/C (6.81%) were found in the 44 HBsAg-positive mothers. The mutation rates of the S gene, in both genotypes B (0.58% vs 1.41%, P = 0.040) and C (7.56% vs 14.71%, P＜0.001), were lower in group T than in group C. Missense substitutions such as L84I, P47S, K10Q, A41P, M133L, A60V, and I42T only existed in group C. The mutation rates of G73S, I126T, and I126S in group C were higher (P < 0.001, P < 0.001, P = 0.010). Deletions occurred in the S gene. The occurrence of intrauterine transmission with maternal mutation A90V was higher (P < 0.001). This may have increased the risk of neonatal HBsAg expression (P = 0.022). Conclusions: The HBV S gene mutations of HBsAg-positive mothers may reduce the occurrence of HBV intrauterine transmission. It is possible for HBsAg-positive mothers infected with A90V to develop HBV chronic infection and transmit it to the fetus during pregnancy, resulting in neonatal HBV infection.

scholarly journals The efficacy and safety of methylprednisolone in hepatitis B virus-related acute-on-chronic liver failure: a prospective multi-center clinical trial

BMC Medicine ◽  
2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Lin Jia ◽  
Ran Xue ◽  
Yueke Zhu ◽  
Juan Zhao ◽  
Juan Li ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Dna Replication ◽  
Hepatitis B ◽  
Liver Failure ◽  
Standard Treatment ◽  
Hbv Dna ◽  
Control Group ◽  
Efficacy And Safety ◽  
Chronic Liver Failure ◽  
B Virus

Abstract Background Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a severe condition with high mortality due to lack of efficient therapy. Until now, the use of methylprednisolone (MP) in HBV-ACLF is still controversial. We aimed to evaluate the efficacy and safety of MP in HBV-ACLF. Methods Totally 171 HBV-ACLF patients from three medical centers were randomly allocated into MP group (83 patients treated with MP intravenously guttae for 7 days plus standard treatment: 1.5 mg/kg/day [day 1–3], 1 mg/kg/day [day 4–5], and 0.5 mg/kg/day [day 6–7]) and control group (88 patients treated with standard treatment). The primary endpoints were 6-month mortality and prognostic factors for 6-month survival. The survival time, cause of death, adverse events, liver function, and HBV DNA replication were analyzed. Results The 6-month mortality was significantly lower in MP group than control group [32.4% vs. 42.5%, P = 0.0037]. MP treatment was an independent prognostic factor for 6-month survival [HR (95% CI) 0.547(0.308–0.973); P = 0.040]. Factors associated with reduced 6-month mortality in MP group included HBV DNA and lymphocyte/monocyte ratio (LMR) (P < 0.05). Based on ROC curve, LMR+MELD had a better predictive value for prognosis of HBV-ACLF under MP treatment. No significant difference in HBV DNA replication was observed between groups (P > 0.05). Conclusions MP therapy is an effective and safe clinical strategy in HBV-ACLF, increasing the 6-month survival rate. Clinical trials registered at http://www.chictr.org.cn as ChiCTR-TRC-13003113 registered on 16 March 2013.

scholarly journals Hepatitis B virus and primary liver cancer

1978 ◽  
Vol 74 (1) ◽  
pp. 163 ◽  
Author(s):  
Thomas V. Nowak ◽  
Brian W. Kennedy ◽  
Lawrence S. Hurwitz ◽  
Rajiv R. Varma
Keyword(s):  
Hepatitis B Virus ◽  
Liver Cancer ◽  
Hepatitis B ◽  
Primary Liver Cancer ◽  
B Virus

scholarly journals THE RISK OF HEPATOCELLULAR CARCINOMA ON PATIENTS DIAGNOSED WITH HEPATITIS B AND HEPATITIS D (2012-2015)

2016 ◽  
Vol 63 (2) ◽  
pp. 153-158
Author(s):  
Irina Dinu ◽  
◽  
Mihai Voiculescu ◽  
Andreea Radasan ◽  
◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis B Virus ◽  
Liver Cancer ◽  
Hepatitis B ◽  
Urban Areas ◽  
Primary Liver Cancer ◽  
Close Monitoring ◽  
Hepatitis D ◽  
Mortality And Morbidity ◽  
B Virus

Introduction. Hepatocellular carcinoma is the most common primary liver cancer (90%), the 5th neoplasia in terms of incidence and the 3rd mortality cause worldwide (1). This increased mortality is the consequence of diagnosis in an advanced state and of the fact that most HCC develop based on a chronic hepatic pathology. In Romania, around 7% of the population is affected by chronic hepatitis B, the incidence of this disease being increased in urban areas (2). The sooner the hepatitis B virus infection occurs in life, the higher the probability is, for this to become chronic and to lead to cirrhosis or liver cancer. Hepatitis D only occurs among people who are infected with the Hepatitis B virus because HDV is an incomplete virus that requires the helper function of HBV to replicate. Objective of the study. The main purpose of the surveillance and/or screening is to decrease mortality and morbidity by means of liver cancer for patients diagnosed with hepatitis B and hepatitis D. Matherial and methods. The study was conducted on a number of 102 patients diagnosed with viral hepatitis (HBV, HDV+HBV) admitted at the “Fundeni” Hospital, Bucharest, between 2012-2015. Two batches of patients were taken into account (patients with hepatitis B and hepatitis D). The viral load and chosen treatment were clinically, biochemically and imagistically evaluated. Results. We have noticed a significant increase in patients diagnosed with hepatitis B and D. The existence of the hepatitis D infection in patients diagnosed with hepatitis B significantly increases the occurence potential of liver cancer. The hepatic destruction degree by means of cirrhotic liver occurence respectively hepatic cirrhosisis much higher for patients diagnosed with hepatitis D. Conclusions. The close monitoring of the patients in this research program brings real benefit for the prevention of liver cancer and diagnosing it early, having a much better prognosis on the quality of life.

scholarly journals Real Time PCR HBV-DNA Analysis in HBsAg Positive Patients

2015 ◽  
Vol 10 (2) ◽  
pp. 95-99
Author(s):  
Wasila Rahman ◽  
Muhammad Rabiul Hossain ◽  
Arif Ahmed Khan ◽  
Debashish Saha ◽  
SM Mahbubul Alam ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Antiviral Therapy ◽  
Real Time ◽  
Real Time Pcr ◽  
Armed Forces ◽  
Hbv Dna ◽  
Health Concern ◽  
B Virus ◽  
Pcr Method

Introduction: The hepatitis B virus is a global public health concern and leading cause of chronic liver disease in Bangladesh. For the diagnosis and monitoring of treatment of Hepatitis B virus infection, HBV-DNA detection and quantification is now extensively used worldwide.Objectives: The objective of this study was to detect HBV-DNA by real time PCR method in HBsAg positive patients, to compare the results of HBVDNA detection with HBeAg and Anti-HBe and to monitor the response after antiviral therapy in chronic hepatitis B patients and also to observe the intensity of hepatitis B infection in relation to age and sex.Methods: This was a cross sectional type of study conducted in Armed Forces Institute of Pathology (AFIP), Dhaka Cantonment. In this study, 56 sera of HBsAg positive patients were selected who all were subjected to do HBV-DNA (real time PCR) analysis during the period of 29 July to 30 0ctober, 2013.Results: Out of 56 HBsAg positive patients, HBV-DNA was detected in 34 patients. Among these, 8 (23.5%) patients were HBeAg positive, 16 (47%) patients were anti-HBe positive and 10 (29.5%) were negative for both HBeAg and anti-HBe. Age limit of patients was up to 60 years. HBV-DNA positive patients showed male predominance; 26 (76.5%) patients were male and 8 (23.5%) patients were female. Mean age of the patients was 35±14 years. Among 56 HBsAg positive patients, fifteen were receiving antiviral therapy. Out of them, HBV-DNA was decreased among 4 patients and could not be detected among 11 patients.Conclusion: Real time PCR method of detection of HBV-DNA is very important in patients who are HBeAg negative and this method is also applied to monitor treatment response to antivirals and to detect occult HBV infections immune control phase and also to detect reactivation of HBV cases.Journal of Armed Forces Medical College Bangladesh Vol.10(2) 2014

Sign in / Sign up

Export Citation Format

Share Document